Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer

Overview

The chemotherapy monitoring is currently based on radiological (RECIST 1.1 guideline) and clinical evaluation every 3 months. Circulating markers as Carcino Embryonic Antigen (CEA), circulating tumour DNA and total cell free DNA represent an alternative approach to evaluate the response. In the field of metastatic colorectal cancer (mCRC) recent studies suggest that early evaluation could be clinically relevant. Indeed, early tumoral response seems to be correlated to overall survival. Moreover, post-operative morbidity increases with the number of prior chemotherapy treatments. Early evaluation could allow to modify chemotherapy regimens when response appears to be insufficient.

The aim of the present study is to evaluate, in a prospective cohort of patients treated with systemic IV chemotherapy (5 Fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy as first line treatment for a mCRC, the correlation between early variations of circulating tumour markers including CEA, circulating tumour DNA and total cell free DNA, and the 3 months objective response as defined in the RECIST 1.1 guideline.

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2020

Interventions

  • Procedure: Blood sampling for free mutant DNA analysis
    • Blood sampling for Patients Treated for Metastatic Colorectal cancer

Arms, Groups and Cohorts

  • Experimental: Patients Treated for Metastatic Colorectal cancer
    • Blood sampling for free mutant DNA analysis for Patients Treated for Metastatic Colorectal cancer

Clinical Trial Outcome Measures

Primary Measures

  • Difference from baseline in the number of free mutant DNA in blood
    • Time Frame: 5 weeks
    • Variation of free mutant DNA kinetic at week 5 to predict tumor progression at 3 months (Evaluation based on the RECIST 1.1 guideline)

Secondary Measures

  • Difference from baseline in the number of free mutant DNA in blood
    • Time Frame: 3 weeks
    • Variation of free mutant DNA kinetic at week 3 to predict tumor progression at 3 months (Evaluation based on the RECIST 1.1 guideline)
  • Evaluation of response based on the RECIST 1.1 guideline
    • Time Frame: 3 Months
    • sensitivity and specificity of free mutant DNA kinetic at Week 5 (RECIST) to predict tumor progression at 3 months (RECIST)

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female, age superior to 18 years.
  • Histologically confirmed metastatic colorectal adenocarcinoma.
  • Measurable disease according to the RECIST 1.1 guideline
  • ECOG performance status <3.
  • Disease requiring IV chemotherapy (5 Fluorouracil +/- oxaliplatin +/- irinotecan) +/ targeted therapy (cetuximab or panitumumab or bevacizumab) every 14 days
  • No prior chemotherapy for this adenocarcinoma with the exception of adjuvant chemotherapy
  • Signed and dated informed consent document.

Exclusion Criteria

  • Medical history of cancer within 5 years
  • Medical contraindication for a treatment consisted of IV chemotherapy (5 Fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy (cetuximab or panitumumab or bevacizumab)
  • Patient with known psychiatric or substance abuse disorders that could interfere with cooperation with the requirements of the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Rouen
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alice GANGLOFF, MD, Principal Investigator, Rouen University Hospital
  • Overall Contact(s)
    • Alice GANGLOFF, MD, alice.gangloff@chu-rouen.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.